Loading patent…
AssigneeEpiontis GmbH
InventorsSven Olek, Tim Schwachula, Udo Baron
Estimating the term…
The present invention relates to a method, in vitro or in vivo, for determining cancer patient survival, comprising analyzing the number and/or amount of tumor-infiltrating overall T-lymphocytes (oTLs) based on the methylation status of at least one CpG position in one or more of the genes for CD3 γ, -δ, and -ε in a tumor sample derived from said cancer patient, wherein a high number and/or amount of oTLs is indicative for a better survival of said cancer patient in a non-breast cancer, wherein in breast cancer a high number and/or amount of oTLs is indicative for an inferior survival of said patient. The present invention also relates to a respective kit for use in the methods of the invention.
A method for determining cancer patient survival, comprising analyzing a number and/or amount of tumor-infiltrating overall T-lymphocytes (oTLs) based on a methylation status of at least one CpG position in one or more genes for CD3 γ, -δ, and -ε in a tumor sample derived from said cancer patient, wherein a high number and/or amount of oTLs is indicative for a better survival and/or better progression free survival in a non-breast cancer patient, and wherein a high number and/or amount of oTLs is indicative for an inferior survival and/or inferior progression free survival in a breast cancer patient.
Dependencies are inferred from the claim text.